Study of ctDNA to Predict Outcomes in New Cases of Ewing Sarcoma or Osteosarcoma

Phase: Recruiting

Condition(s): Ewing Sarcoma, Osteosarcoma

NCT Number: NCT06068075 Other Study ID Number(s): ctDNA

What Is the Purpose of This Study?

This study evaluates whether circulating tumor deoxyribonucleic acid (ctDNA) in the blood can provide information about the chances of Ewing sarcoma or osteosarcoma coming back after treatment and locate specific genetic alterations.

Who Can Take Part in This Study?

People who may be eligible for this study:

  • Are 12 months old at time of study enrollment to 50 years old.
  • Have histologic diagnosis (by institutional pathologist) of newly diagnosed, localized or regionally disseminated Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) of bone or soft tissue.
  • Or have histologic diagnosis (by institutional pathologist) of newly diagnosed, non-pelvic, localized or regionally disseminated high-grade osteosarcoma.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT06068075

 

What Will Happen During This Study?

PART A: Patients undergo blood sample collection throughout the study. Physicians and patients do not receive any return of results of the ctDNA analysis on study.

PART B: Patients undergo blood sample collection during follow-up. Physicians receive ctDNA return of results and discuss results with patients/parents. Patients/parents and providers complete surveys prior to receipt of first ctDNA return of results and after discussion of ctDNA return of results.

Principal Investigator

Bhuvana A. Setty
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to sarcoma and solid tumors